Breast Cancer Clinical Trial
— CANUT-2Official title:
Impact of a Nutritional, Sensory and Culinary Support on the Improvement of the Quality of Life Related to Meals in Patients With Cancer Cancer Patients Treated With Chemotherapy
Verified date | October 2023 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Although it has been established that the perception of food and eating and cooking habits change during cancer and its treatment, quality of life related to meals, which is an indicator of the psychobiological and physiological well-being of patients in their relationship to food, has been little studied in the pathological context, and particularly in patients undergoing chemotherapy. Beyond its biological role, food plays a significant psychobiological and social role, as shown by a series of qualitative studies based on interviews with patients. Following a cancer diagnosis, loss of appetite, difficulty in sharing a meal with the family, and reduced pleasure in eating disrupt the patient's relationship with his or her food. Thus, side effects such as fatigue, nausea and vomiting, and alterations in taste and smell induced by chemotherapy will affect patients' eating behavior, increasing the risk of deteriorating their quality of life with food. As these side effects are less known and therefore less expected by patients, they often lack the information and tools necessary to understand them. The present study proposes a support for cancer patients treated by chemotherapy in order to improve their quality of life related to meals, and thus keep the pleasure of eating and reduce the risks of malnutrition. This support will consist of a guide provided to patients, in which they will have information on the functioning of the sensory systems involved in the eating experience, advice and culinary tips to adapt foods to their sensory disorders, and recipes that can be adapted in mild (for patients with hypersensitivity to tastes/smells), accentuated (for patients with hypersensitivity to tastes/smells) and enriched (for patients at risk of denutrition) versions. In addition, their sensory abilities will be assessed at the beginning of the study by psychophysical tests, then between each chemotherapy via a telephone interview (self-reported sensory abilities), and they will benefit from orientation according to the test results. This work will be a first action to improve the quality of life related to the meal by information, follow-up, and adaptation of the meals to the sensory performances of each patient.
Status | Completed |
Enrollment | 209 |
Est. completion date | September 21, 2023 |
Est. primary completion date | September 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Major patient with one of the following 3 types of cancer: - Stage 4 lung cancer (TNM 7 or 8). The indication for immunotherapy in addition to first line chemotherapy will not be a criterion for non-inclusion patients - histologically or cytologically proven localized breast cancer cytologically proven - Gynecological cancer (ovarian cancer or uterine cancer) stage III-IV without functional digestive signs related to the tumor disease - Patient with a body mass index (BMI) between 18 Kg/m² and 35 Kg/m². - Patient for whom the indication for treatment with a first line of intravenous chemotherapy (+/- targeted therapy) has been accepted by multidisciplinary meeting. - Patient naive to previous chemotherapy. - Life expectancy > 3 months. - Patient with written informed consent - Patient affiliated to a French social security system. Exclusion Criteria: - Patient under 18 years - Patient who had another malignancy within the last 3 years years, with the exception of carcinoma in situ of the cervix or cervical carcinoma in situ or adequately treated squamous cell carcinoma of the skin adequately treated, or basal cell skin cancer.This cancer must be adequately controlled. - Patients with symptomatic brain and/or meningeal metastases. - Patients with symptomatic mucositis. - Patients suffering or having suffered from an ear, nose and throat disease or oeso-gastro intestinal pathology interfering with the food intake. - Patients suffering from digestive disorders such as nausea prior to any cancer treatment. - Indication of concomitant radiotherapy or immunotherapy treatment alone. - Patients with a known food allergy or intolerance - Patient with diagnosed partial or total ageusia. - Patient with diagnosed partial or total anosmia. - Patient having used artificial feeding in the 2 months prior to inclusion. - Patient who has lost more than 10% of baseline weight in the 2 months prior to inclusion. - Patient unable to be regularly followed for any reason (geographical, family, social, psychological,...). - Patient deprived of liberty or placed under guardianship or legal protection. - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Louis Pradel, Service gynécologie | Bron | |
France | Hôpital Louis Pradel, Service pneumologie | Bron | |
France | Infirmerie Protestante | Caluire-et-Cuire | |
France | Centre Léon Bérard, service gynécologie | Lyon | |
France | Centre Léon Bérard, service pneumologie | Lyon | |
France | Hôpital de la Croix Rousse, service pneumologie | Lyon | |
France | Centre hospitalo-universitaire de Lyon Sud, service Oncologie médicale | Pierre-Bénite | |
France | Centre hospitalo-universitaire de Lyon Sud, service pneumologie | Pierre-Bénite | |
France | CHU St Etienne, | Saint-Étienne | |
France | CH de Valence | Valence |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | QVA questionnaire score difference between the 2 arms | The main endpoint of CANUT-2 is the comparison of the overall score of the food quality of life questionnaire (Qualité de Vie Alimentaire QVA) between patients who received CANUT support and those who did not receive the CANUT support. The comparison is performed at the time of V2 i.e. after 4 cycles of chemotherapy treatment, corresponding with the end of study follow-up. | At the end of study follow-up, up to 12 weeks | |
Secondary | QVA questionnaire score | Food questionnaire score QVA will be compared for each subsection between the 2 groups and between V1 (inclusion) and V2 (after 4 cycles of chemotherapy), according to the type of cancer. | At the end of study follow-up, up to 12 weeks | |
Secondary | QLQ-C30 score | Quality of life questionnaire score QLQ-C30 will be compared between the 2 arms and between V1 and V2, according to the type of cancer | At the end of study follow-up, up to 12 weeks | |
Secondary | Weight | Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. | At the end of study follow-up, up to 12 weeks | |
Secondary | waist size | Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. | At the end of study follow-up, up to 12 weeks | |
Secondary | hip size | Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. | At the end of study follow-up, up to 12 weeks | |
Secondary | brachial circumference | Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. | At the end of study follow-up, up to 12 weeks | |
Secondary | Prehension strength | This parameter, associated with anthropometric parameters and 24 H feedback questionnaire score, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer | At the end of study follow-up, up to 12 weeks | |
Secondary | 24 H feedback questionnaire score | This parameter, associated with anthropometric parameters and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer | At the end of study follow-up, up to 12 weeks | |
Secondary | Olfactory capacities | Olfactory capacities will be assessed thanks to the Scratch & Snif Test | At the end of study follow-up, up to 12 weeks | |
Secondary | Taste capacities | Taste capacities will be assessed thanks to the Taste Strip Test | At the end of study follow-up, up to 12 weeks | |
Secondary | Trigeminal sensitivity | Trigeminal sensitivity will be assessed thanks to a trigeminal sensitivity test | At the end of study follow-up, up to 12 weeks | |
Secondary | Use of CANUT guide | Changes in the frequency of use of the CANUT guide | At the end of study follow-up, up to 12 weeks | |
Secondary | Patient typology | Determining patient typology according to CITAS (Chemotherapy-induced Taste Alteration Scale) scale | At the end of study follow-up, up to 12 weeks | |
Secondary | Patient satisfaction | Determining patient satisfaction using a satisfaction questionnaire | At the end of study follow-up, up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |